Thoracic Oncology Program »  Meet the Team »  Medical Oncologists »  Collin Blakely, M.D., Ph.D.

Collin Blakely, M.D., Ph.D.

Assistant Clinical Professor
Division of Hematology/Oncology
Department of Medicine

Contact Information

(415) 885-3882  Patients & Clinic 
(415) 353-9525  Fax
Open Popup
  • University of Washington, B.S. 1997

  • University of Pennsylvania, M.D., Ph.D. 2007
  • Hospital of the University of Pennsylvania, Internship in Internal Medicine, 2007-2008

  • Hospital of the University of Pennsylvania, Residency in Internal Medicine, 2008-2009
  • UCSF, Fellowship in Medical Oncology, 2009-2011
  • Postdoctoral Fellow - UCSF, Lisa Coussens Laboratory, 2010-2012

  • Postdoctoral Fellow - UCSF, Trever Bivona Laboratory, 2012-2014
  • Non-small cell lung cancer
  • Small cell lung cancer
  • ALK-rearranged lung cancer
  • EGFR-mutant lung cancer
  • Mechanisms of resistance to targeted therapies
  • ROS1-rearranged lung cancer

Collin is a medical oncologist specializing in the treatment of lung cancer. He received his Bachelor of Science degree in Molecular and Cellular Biology from the University of Washington and attended the Perelman School of Medicine at the University of Pennsylvania in the Medical Scientist Training Program. He completed his Internal Medicine residency at the Hospital of the University of Pennsylvania and trained as a clinical fellow in Medical Oncology at UCSF. His research focuses on understanding the cellular and molecular mechanisms underlying lung cancer resistance to EGFR-targeted therapies. His goal is to translate laboratory-based findings into new treatments for lung cancer patients.

  • Legacy Award, Uniting Against Lung Cancer, 2014-2016
  • AACR BioOncology Fellowship, AACR, 2014-2016
  • Research Grant, Bonnie J. Addario Lung Cancer Foundation, 2013

The primary focus of my research is to translate laboratory-based findings into novel investigator sponsored trials that aim to assess the safety and efficacy of rationally designed targeted therapies for lung cancer patients.

My goals are to: 1) define how TKI resistance pathways evolve at the tumor genome, transcriptome and molecular signaling levels within lung cancers and to translate these findings into novel prognostic and predictive biomarkers that may predict TKI resistance before it occurs; 2) develop investigator sponsored clinical trials to test rational companion therapies that can prevent, delay, or overcome TKI resistance, 3) develop investigator sponsored clinical trials to target recently identified oncogenic pathways, outside of EGFR and ALK, that drive NSCLC; and 4) establish a cohort of patient-derived xenograft (PDX) mice to foster research that aims to further understand the molecular mechanisms of response and resistance to TKI therapies in lung cancer

  • Uniting Against Lung Cancer, 2014-2016, AACR 2014 - 2016
From a total of 13 publications
  1. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Collin Blakely, M.D., Ph.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X